Search

Displaying results 1311 - 1320 of 4692 in total
  1. Drug

    Hydroxystilbamidine

    go.drugbank.com/drugs/DB14753
    Approved

    Hydroxystilbamidine isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than amphotericin B. Hydroxystilbamidine ...

  2. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain.

  3. Drug

    Fenoprofen

    go.drugbank.com/drugs/DB00573
    Approved

    It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.

  4. Drug

    Methyl aminolevulinate

    go.drugbank.com/drugs/DB00992
    ApprovedInvestigational

    Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

  5. Drug

    Human calcitonin

    go.drugbank.com/drugs/DB06773
    Approved

    Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calci...

  6. Target

    Tyrosine-protein kinase Fes/Fps

    go.drugbank.com/bio_entities/BE0009444
    TargetHumans

    Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading. Plays a role in FCER1 (high affinity immunoglo...

    Synonyms: Feline sarcoma/Fujinami avian sarcoma oncogene homolog
  7. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...

  8. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.

  9. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L39030] This indication is valid in the US, Europe, and Canada. … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.

  10. Drug

    Asunaprevir

    go.drugbank.com/drugs/DB11586
    ApprovedWithdrawn

    [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]